Pharming (PHAR) Non-Current Assets (2019 - 2026)
Pharming's (PHAR) quarterly Non-Current Assets came in at $187.3 million in Q2 2026, down 6.58% YoY from $200.5 million in Q2 2025, and down 3.38% on a QoQ basis from $193.9 million in Q1 2026.
Pharming (PHAR) Non-Current Assets (2019 - 2026) Analysis & Trends
Pharming (PHAR) has 8 years of Non-Current Assets data on file, last reported at $187.3 million in Q2 2026.
- Quarterly Non-Current Assets fell 6.58% year-over-year to $187.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $187.3 million (down 6.58% YoY) and the FY2025 annual result came in at $200.5 million, up 64.96% from the prior year.
- Non-Current Assets retreated to $187.3 million in Q2 2026, from $193.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $200.5 million in Q4 2025 to a low of $130275.0 in Q3 2022.
- A 5-year average of $152.7 million and a median of $147.4 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 99.92% — and 2023, when it surged 110995.76%.
- Tracing PHAR's Non-Current Assets over 5 years: stood at $148.3 million in 2022, then dropped by 1.2% to $146.5 million in 2023, then declined by 17.04% to $121.5 million in 2024, then soared by 64.96% to $200.5 million in 2025, then dropped by 6.58% to $187.3 million in 2026.
- The last three Non-Current Assets figures came in at $187.3 million (Q2 2026), $193.9 million (Q1 2026), and $200.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 187.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.30 Mn |
| Mar 31, 2026 | 193.85 Mn |
| Dec 31, 2025 | 200.50 Mn |
| Sep 30, 2025 | 196.19 Mn |
| Jun 30, 2025 | 200.48 Mn |
| Mar 31, 2025 | 189.08 Mn |
| Dec 31, 2024 | 121.55 Mn |
| Sep 30, 2024 | 143.32 Mn |
| Jun 30, 2024 | 145.30 Mn |
| Mar 31, 2024 | 145.12 Mn |
| Dec 31, 2023 | 146.51 Mn |
| Sep 30, 2023 | 144.73 Mn |
| Jun 30, 2023 | 151.23 Mn |
| Mar 31, 2023 | 156.94 Mn |
| Dec 31, 2022 | 148.30 Mn |
| Sep 30, 2022 | 130,275.00 |
| Jun 30, 2022 | 136.92 Mn |
| Mar 31, 2022 | 141.85 Mn |
| Dec 31, 2021 | 149,250.46 |
| Sep 30, 2021 | 158.73 Mn |